Needham & Company Reiterates a ‘Strong Buy’ on NuVasive (NUVA)

Share this story with your network

April 19, 2010 8:03 AM EDT

Needham & Company reiterates a ‘Strong Buy’ rating on NuVasive Inc. (NasdaqNUVA), price target $60.

Needham analyst says, “We expect significant upside to NUVA’s share price if NUVA continues to meet or beat numbers and demonstrates EPS leverage in 2010.”

To see all the upgrades/downgrades on shares of NUVA, visit our Analyst Ratings page.

NuVasive, Inc. (NuVasive) is a medical device company. It focuses on the designing, developing and marketing of products for the surgical treatment of spine disorders.

Leave a Comment

Your email address will not be published. Required fields are marked *